

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * ESSIG STUART (Last) (First) (Middle) 311 C ENTERPRISE DRIVE (Street) PLAINSBORO NJ 08536 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol INTEGRA LIFESCIENCES HOLDINGS CORP [IART]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/22/2017	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/22/2017		M ⁽¹⁾		44,571	A	\$17.45	1,973,335 ⁽²⁾	D	
Common Stock	05/22/2017		S ⁽¹⁾		44,571	D	\$48.0098 ⁽³⁾	1,928,764	D	
Common Stock	05/23/2017		M ⁽¹⁾		68,780	A	\$17.45	1,997,544	D	
Common Stock	05/23/2017		M ⁽¹⁾		95,429	A	\$17.45	2,092,973	D	
Common Stock	05/23/2017		S ⁽¹⁾		95,429	D	\$48.0139 ⁽⁴⁾	1,997,544	D	
Common Stock	05/23/2017		A		4,587	A	\$0.00	2,002,131	D	
Common Stock	05/23/2017		A		1,564	A	\$0.00	2,003,695	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$17.45	05/22/2017		M ⁽¹⁾			44,571	(5)	12/18/2017	Common Stock	44,571	\$0.00	372,989 ⁽⁶⁾	D	
Non-Qualified Stock Option (right to buy)	\$17.45	05/23/2017		M ⁽¹⁾			68,780	(5)	12/18/2017	Common Stock	68,780	\$0.00	304,209	D	
Non-Qualified Stock Option (right to buy)	\$17.45	05/23/2017		M ⁽¹⁾			95,429	(5)	12/18/2017	Common Stock	95,429	\$0.00	208,780	D	

Explanation of Responses:

- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
- On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date, as reflected in the totals listed on this Form 4.
- The price shown above represents the weighted average price of the shares sold. The range of sale prices was \$48 to \$48.10.
- The price shown above represents the weighted average price of the shares sold. The range of sale prices was \$47.90 to \$48.14.
- 25% of the option grant vested on 12/18/2008 (the first anniversary of the grant date of 12/18/2007), and the remaining 75% vested monthly thereafter over 36 months.
- This stock option was previously reported as covering 208,780 shares of common stock at an exercise price of \$34.90 per share. In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016.

Remarks:

/s/ Richard D. Gorelick;

05/24/2017

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.